17.32 0.00 (0.00%)
After hours: 4:00PM EST
|Bid||17.31 x 1400|
|Ask||17.33 x 1100|
|Day's Range||17.14 - 17.86|
|52 Week Range||15.18 - 29.45|
|Beta (3Y Monthly)||1.65|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.67|
DUBLIN , Nov. 6, 2019 /PRNewswire/ -- November 6, 2019 – Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that management will participate in a corporate presentation at the 28th Annual Credit ...
Theravance's (TBPH) third-quarter loss matches estimates while revenues miss the same in absence of product sales due to the sale of its only marketed drug Vibativ to Cumberland Pharmaceuticals.
Theravance Bio (TBPH) delivered earnings and revenue surprises of 0.00% and -6.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Late-stage clinical studies of ampreloxetine and gut-selective oral pan-JAK inhibitor TD-1473 progressing - Lung-selective inhaled pan-JAK inhibitor TD-8236 progressing to allergen challenge study following ...
DUBLIN, Oct. 29, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended September 30, 2019 and provide a business update after market close on Tuesday, November 5, 2019. To participate in the live call by telephone, please dial (855) 296-9648 from the US, or (920) 663-6266 for international callers, using the confirmation code 6281636. A replay of the conference call will be available on Theravance Biopharma's website for 30 days through December 5, 2019.
Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Oct. 21, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that data from studies of YUPELRI® (revefenacin) inhalation solution will be presented at CHEST 2019, the annual meeting of the American College of Chest Physicians, on Oct. 22 in New Orleans, LA. Data will include results from a phase 3b trial on YUPELRI when given before or combined with Perforomist® (formoterol fumarate) inhalation solution via nebulization in patients with chronic obstructive pulmonary disease (COPD).
Theravance's (TBPH) newly-launched COPD drug Yupelri is witnessing a solid adoption while its pipeline programs are also progressing well. However, excessive reliance on Yupelri for revenues is a woe.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
DUBLIN , Sept. 25, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that management will participate in a fireside chat at the 2019 Cantor Global Healthcare Conference on ...
Theravance's (TBPH) investigational JAK inhibitor TD-8236 demonstrates favorable results from a phase I study for treating inflammatory lung diseases.
DUBLIN, Sept. 9, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced initial results, including positive biomarker responses, from its Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial of TD-8236, an investigational, lung-selective inhaled pan-Janus kinase (JAK) inhibitor for inflammatory lung diseases. TD-8236 is specifically designed to be delivered to the lung via dry powder inhalation, targeting airway inflammation in the lung with minimal systemic exposure.
DUBLIN , Aug. 28, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will participate in fireside chats at two upcoming investor conferences: 14 th ...
Anyone researching Theravance Biopharma, Inc. (NASDAQ:TBPH) might want to consider the historical volatility of the...
Achillion (ACHN) meets bottom-line estimates in the second quarter. The absence of an approved product results in no revenues in the quarter.